CPA
AMED

Capital Performance Advisors’s Amedisys AMED Stock Holding History

Capital Performance Advisors’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18
Closed -$1.74K – 290
2024
Q3 		$1.74K Buy
+18
New +$1.76K ﹤0.01% 1633

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Capital Performance Advisors's AMED Position: Q4 2024 in Review

Capital Performance Advisors sold out of Amedisys (AMED) in Q4 2024, closing a stake of 18 shares — an estimated $1.74K sold.

Capital Performance Advisors first reported a position in AMED in Q3 2024 and held it in 1 quarter. The position peaked at $1.74K in Q3 2024. 290 funds tracked by Wall St. Rank hold AMED as of Q4 2024.

  • Capital Performance Advisors reported no remaining Amedisys position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 18 Amedisys shares in Q4 2024, an estimated $1.74K.
  • Capital Performance Advisors first reported a position in Amedisys in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Amedisys position peaked at $1.74K in Q3 2024.
  • 290 funds tracked by Wall St. Rank held Amedisys as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.